Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
作者： Sai-Hong Ignatius Ou , Samuel J. Klempner , Joel R. Greenbowe , Michele Azada , Alexa B. Schrock
DOI: 10.1097/JTO.0000000000000368
关键词:
摘要: … kinase (ALK) in non–small-cell lung cancer (NSCLC). To date, two variants of HIP1-ALK (H21; … However, the response of patients with NSCLC harboring HIP1-ALK to ALK inhibitors and …
jto.org
sci-hub.se 参考文章(14)
Theodora S. Ross, Olivier A. Bernard, Roland Berger, D. Gary Gilliland, Fusion of Huntingtin Interacting Protein 1 to Platelet-Derived Growth Factor β Receptor (PDGFβR) in Chronic Myelomonocytic Leukemia With t(5;7)(q33;q11.2) Blood. ,vol. 91, pp. 4419- 4426 ,(1998) , 10.1182/BLOOD.V91.12.4419.412K43_4419_4426
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson, Victor M. Rivera, Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chemical Biology & Drug Design. ,vol. 78, pp. 999- 1005 ,(2011) , 10.1111/J.1747-0285.2011.01239.X
A. P. Kornev, N. M. Haste, S. S. Taylor, L. F. Ten Eyck, Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 17783- 17788 ,(2006) , 10.1073/PNAS.0607656103
Mineui Hong, Ryong Nam Kim, Ji-Young Song, So-Jung Choi, Ensel Oh, Maruja E. Lira, Mao Mao, Kengo Takeuchi, Joungho Han, Jhingook Kim, Yoon-La Choi, HIP1–ALK, a Novel Fusion Protein Identified in Lung Adenocarcinoma Journal of Thoracic Oncology. ,vol. 9, pp. 419- 422 ,(2014) , 10.1097/JTO.0000000000000061
Sai-Hong Ignatius Ou, Michele Azada, David J. Hsiang, June M. Herman, Tatiana S. Kain, Christina Siwak-Tapp, Cameron Casey, Jie He, Siraj M. Ali, Samuel J. Klempner, Vincent A. Miller, Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib Journal of Thoracic Oncology. ,vol. 9, pp. 549- 553 ,(2014) , 10.1097/JTO.0000000000000094
Yaël P Mossé, Marci Laudenslager, Luca Longo, Kristina A Cole, Andrew Wood, Edward F Attiyeh, Michael J Laquaglia, Rachel Sennett, Jill E Lynch, Patrizia Perri, Geneviève Laureys, Frank Speleman, Cecilia Kim, Cuiping Hou, Hakon Hakonarson, Ali Torkamani, Nicholas J Schork, Garrett M Brodeur, Gian P Tonini, Eric Rappaport, Marcella Devoto, John M Maris, None, Identification of ALK as a major familial neuroblastoma predisposition gene Nature. ,vol. 455, pp. 930- 935 ,(2008) , 10.1038/NATURE07261
Tatsushi Kodama, Toshiyuki Tsukaguchi, Miyuki Yoshida, Osamu Kondoh, Hiroshi Sakamoto, Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Letters. ,vol. 351, pp. 215- 221 ,(2014) , 10.1016/J.CANLET.2014.05.020
Alice T. Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J. Solomon, Fiona Blackhall, Yi-Long Wu, Michael Thomas, Kenneth J. O'Byrne, Denis Moro-Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne, Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer The New England Journal of Medicine. ,vol. 368, pp. 2385- 2394 ,(2013) , 10.1056/NEJMOA1214886
Daria Zdzalik, Barbara Dymek, Paulina Grygielewicz, Pawel Gunerka, Anna Bujak, Monika Lamparska-Przybysz, Maciej Wieczorek, Karolina Dzwonek, Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma Journal of Cancer Research and Clinical Oncology. ,vol. 140, pp. 589- 598 ,(2014) , 10.1007/S00432-014-1589-3
Douglas D. Fang, Bin Zhang, Qingyang Gu, Maruja Lira, Qiang Xu, Hongye Sun, Maoxiang Qian, Weiqi Sheng, Mark Ozeck, Zhenxiong Wang, Cathy Zhang, Xinsheng Chen, Kevin X. Chen, Jian Li, Shu-Hui Chen, James Christensen, Mao Mao, Chi-Chung Chan, HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib Journal of Thoracic Oncology. ,vol. 9, pp. 285- 294 ,(2014) , 10.1097/JTO.0000000000000087